Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
What we have learned from the Myriad trials.
Hendrix SB, Wilcock GK. Hendrix SB, et al. J Nutr Health Aging. 2009 Apr;13(4):362-4. doi: 10.1007/s12603-009-0044-7. J Nutr Health Aging. 2009. PMID: 19300881 No abstract available.
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P; EU/US/CTAD Task Force Members. Vellas B, et al. Among authors: hendrix s. Alzheimers Dement. 2013 Jul;9(4):438-44. doi: 10.1016/j.jalz.2013.03.007. Alzheimers Dement. 2013. PMID: 23809364
Statistical properties of continuous composite scales and implications for drug development.
Liu-Seifert H, Andersen S, Case M, Sparks J, Holdridge KC, Wessels AM, Hendrix S, Aisen P, Siemers E. Liu-Seifert H, et al. Among authors: hendrix s. J Biopharm Stat. 2017;27(6):1104-1114. doi: 10.1080/10543406.2017.1315819. Epub 2017 Apr 27. J Biopharm Stat. 2017. PMID: 28402165
Report of the task force on designing clinical trials in early (predementia) AD.
Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B. Aisen PS, et al. Among authors: hendrix sb. Neurology. 2011 Jan 18;76(3):280-6. doi: 10.1212/WNL.0b013e318207b1b9. Epub 2010 Dec 22. Neurology. 2011. PMID: 21178097 Free PMC article.
Prevention trials in Alzheimer's disease: an EU-US task force report.
Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni GB, Weiner M, Schneider L, Gauthier S, Gispen-de Wied CC, Hendrix S, Feldman H, Cedarbaum J, Petersen R, Siemers E, Andrieu S, Prvulovic D, Touchon J, Hampel H. Vellas B, et al. Among authors: hendrix s. Prog Neurobiol. 2011 Dec;95(4):594-600. doi: 10.1016/j.pneurobio.2011.08.014. Epub 2011 Sep 10. Prog Neurobiol. 2011. PMID: 21925234
Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis.
Atri A, Hendrix SB, Pejović V, Hofbauer RK, Edwards J, Molinuevo JL, Graham SM. Atri A, et al. Among authors: hendrix sb. Alzheimers Res Ther. 2015 May 18;7(1):28. doi: 10.1186/s13195-015-0109-2. eCollection 2015. Alzheimers Res Ther. 2015. PMID: 25991927 Free PMC article.
Methodological Aspects of the Phase II Study AFF006 Evaluating Amyloid-beta -Targeting Vaccine AFFITOPE® AD02 in Early Alzheimer's Disease - Prospective Use of Novel Composite Scales.
Hendrix S, Ellison N, Stanworth S, Tierney L, Mattner F, Schmidt W, Dubois B, Schneeberger A. Hendrix S, et al. J Prev Alzheimers Dis. 2015 Jun;2(2):91-102. doi: 10.14283/jpad.2015.67. J Prev Alzheimers Dis. 2015. PMID: 26866015 Free PMC article.
Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force.
Sano M, Soto M, Carrillo M, Cummings J, Hendrix S, Mintzer J, Porsteinsson A, Rosenberg P, Schneider L, Touchon J, Aisen P, Vellas B, Lyketsos C. Sano M, et al. Among authors: hendrix s. J Prev Alzheimers Dis. 2018;5(2):98-102. doi: 10.14283/jjpad.2018.15. J Prev Alzheimers Dis. 2018. PMID: 29616702 Free PMC article.
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort.
Tariot PN, Lopera F, Langbaum JB, Thomas RG, Hendrix S, Schneider LS, Rios-Romenets S, Giraldo M, Acosta N, Tobon C, Ramos C, Espinosa A, Cho W, Ward M, Clayton D, Friesenhahn M, Mackey H, Honigberg L, Sanabria Bohorquez S, Chen K, Walsh T, Langlois C, Reiman EM; Alzheimer's Prevention Initiative. Tariot PN, et al. Among authors: hendrix s. Alzheimers Dement (N Y). 2018 Mar 8;4:150-160. doi: 10.1016/j.trci.2018.02.002. eCollection 2018. Alzheimers Dement (N Y). 2018. PMID: 29955659 Free PMC article.
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
Lawlor B, Segurado R, Kennelly S, Olde Rikkert MGM, Howard R, Pasquier F, Börjesson-Hanson A, Tsolaki M, Lucca U, Molloy DW, Coen R, Riepe MW, Kálmán J, Kenny RA, Cregg F, O'Dwyer S, Walsh C, Adams J, Banzi R, Breuilh L, Daly L, Hendrix S, Aisen P, Gaynor S, Sheikhi A, Taekema DG, Verhey FR, Nemni R, Nobili F, Franceschi M, Frisoni G, Zanetti O, Konsta A, Anastasios O, Nenopoulou S, Tsolaki-Tagaraki F, Pakaski M, Dereeper O, de la Sayette V, Sénéchal O, Lavenu I, Devendeville A, Calais G, Crawford F, Mullan M; NILVAD Study Group. Lawlor B, et al. Among authors: hendrix s. PLoS Med. 2018 Sep 24;15(9):e1002660. doi: 10.1371/journal.pmed.1002660. eCollection 2018 Sep. PLoS Med. 2018. PMID: 30248105 Free PMC article. Clinical Trial.
The a priori defined primary outcome was progression on the Alzheimer's Disease Assessment Scale Cognitive Subscale-12 (ADAS-Cog 12) in the modified intention-to-treat (mITT) population (n = 498), with the Clinical Dementia Rating Scale sum of boxes (CDR-sb) as a gated co- …
The a priori defined primary outcome was progression on the Alzheimer's Disease Assessment Scale Cognitive Subscale-12 (ADAS-Cog 12) in the …
19 results
Jump to page
Feedback